ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR073

Increased Short-Term and Long-Term Mortality in Community- and Hospital-Acquired Hypernatremia and in Patients with Delayed Sodium Correction

Session Information

Category: Fluid and Electrolytes

  • 902 Fluid and Electrolytes: Clinical


  • Thongprayoon, Charat, Mayo Clinic, Rochester, Minnesota, United States
  • Cheungpasitporn, Wisit, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Qian, Qi, Mayo Clinic, Rochester, Minnesota, United States

This study examined short- and long-term mortality (i) in a large cohort of general hospitalized adults with community- and hospital-acquired hypernatremia and (ii) in hypernatremic patients with and without serum [Na+] correction within three days of hospital stay.


Adult patients admitted to Mayo Clinic Rochester in a three-year (2011-2013) period were examined. Patients were categorized into 3 groups based on serum [Na+] at admission and during hospitalization; 1) normal serum [Na+], 2) community-acquired hypernatremia, and 3) hospital-acquired hypernatremia. Normal serum [Na+] was defined as serum [Na+] at admission and all during hospitalization within 138-142 mEq/L. Community-acquired hypernatremia was defined as serum [Na+] at admission ≥ 143 mEq/L, whereas hospital-acquired hypernatremia was defined as serum [Na+] at admission 138-142 mEq/L but any serum [Na+] during hospitalization ≥ 143 mEq/L. Outcomes included hospital and 1-year mortality


Of the total 25,781 patients, 44.7% (n=11,531) were normonatremic, 20.3% (n=5,229) were community-acquired hypernatremia and 35.0% were hospital acquired hypernatremia. In fully adjusted models, ORs (95% CIs) for hospital mortality and HRs (95% CIs) for one-year mortality were 4.91 (3.47-6.94) and 2.25 (2.01-2.53) for community-acquired and 4.11 (2.94-5.73) and 2.35 (2.12-2.60) for hospital-acquired hypernatremia. Hospital-acquired hypernatremia showed a higher hospital, but not one-year, mortality than community-acquired hypernatremia. Among patients with community-acquired hypernatremia, 36.1% (n=1,893) remained hypernatremic by hospital day three ([Na+] 145±3 mEq/L). Fully adjusted hospital- and one-year mortality were significantly increased in patients without [Na+] correction, 3.01 (2.01-4.49), 1.51 (1.26-1.81), respectively, compared to those with [Na+] correction.


Hypernatremia, regardless of acquisition origin, is associated with elevated short-term and long-term mortality. Hospital-acquired hypernatremia was more common and had a higher short-term mortality than community-acquired hypernatremia. Failure to correct hypernatremia by hospital day three is associated with increased morbidity and mortality.